Key statistics
On Monday, Genfit SA (GNFTF:PKL) closed at 5.55, 0.00% below its 52-week high of 5.55, set on Oct 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.55 |
---|---|
High | 5.55 |
Low | 5.55 |
Bid | -- |
Offer | -- |
Previous close | 5.55 |
Average volume | 400.00 |
---|---|
Shares outstanding | 49.94m |
Free float | 43.42m |
P/E (TTM) | 14.98 |
Market cap | 254.69m EUR |
EPS (TTM) | 0.3404 EUR |
Data delayed at least 15 minutes, as of Oct 07 2024 15:34 BST.
More ▼
Announcements
- GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA américaine
- GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
- GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
- GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société
- GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
- GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
- GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
- GENFIT : Les nouvelles recommandations de pratique clinique de l'EASL-EASD-EASO pour la MASLD incluent NIS2+® comme outil-clé pour la détection de la MASH à risque
- GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
More ▼